Open AccessA phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors
Author(s) -
Adam L. Cohen,
Abhijit Ray,
Matthew Van Brocklin,
Dave Burnett,
Randy C. Bowen,
Donna L. Dyess,
Thomas W. Butler,
Theresa Dumlao,
Hung T. Khong
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.14183
Subject(s) - medicine , paclitaxel , cancer , oncology , salt lake , paleontology , structural basin , biology
Secreted protein acidic and rich in cysteine (SPARC), an albumin-binding protein, is downregulated by hypermethylation in many cancers. Hypomethylating agents such as azacitidine can upregulate SPARC in tumors, which may enhance the accumulation of albumin-bound drugs at tumor site. The objectives of this phase I trial was to determine the safety and maximum tolerated dose and to assess any clinical activity of the combination of azacytidine and weekly nanoparticle-albumin-bound (nab®) paclitaxel.